Privacy, patents and property
While both life sciences and technology companies face a number of strategic, operational and cultural obstacles, they also need to understand several pressing legal issues in order to succeed in digital healthcare.
Data dilemmas More than half of our respondents—in both the technology and life sciences sectors—said their digital healthcare strategies will require them to collect, store and transfer individuals’ health information. Of these, 44 percent of technology companies and 32 percent of life sciences companies said this will involve the transfer of data outside the United States, which means they could become subject to the privacy laws of additional jurisdictions like the EU.
There is plenty of uncertainty over the legal issues involved in doing this. In our survey, a lack of any standardized global privacy regulations was, by far, the most frequently mentioned data privacy issue, with 73 percent of respondents seeing this as a problem that could stifle growth in digital healthcare. Respondents want global standards (even among all EU member states and US states) to reduce their legal and compliance issues and costs.
“Global standards would make a huge difference in speeding up our development programs,” said one life sciences Digital Strategy Director.
When trying to address these data privacy concerns, those surveyed said they would be most likely to focus their communication efforts on regulators (85 percent), patients (71 percent) and payers (66 percent).
The key for companies dealing with these data issues is to start early, plan accordingly and take control, according to Daren Orzechowski.
“Digital healthcare businesses need to think about data privacy elements from the start,” he says. “They should focus on privacy issues when they start developing new products and defining the user experience, and, at that time, try to determine how their company will use the data it collects.”
A company that can solve how to rapidly share information, get patient consents for data sharing efficiently and satisfy regulators will have a great deal of opportunities in the market. “No one is fully realizing this opportunity yet,” says Orzechowski. “But someone could create a platform that would bring this all together.”
Protecting your property IP issues were seen as a barrier to the growth of digital healthcare by 81 percent of the technology respondents and 75 percent of the life sciences respondents. Of those who saw IP concerns as a barrier to growth, 40 percent said the biggest barrier is the slow (up to three- or four-year) process for obtaining patents amid rapid innovation. Meanwhile, 15 percent and 27 percent pointed to the specific difficulty of getting patent protection for software applications and abstract ideas as the biggest or second-biggest barrier to growth, respectively.
Yet for companies fearful that not getting a patent might impede their strategic growth, there are ways to speed up the patent review process or, in some cases, bypass it altogether. “In the United States, for example, it is sometimes possible to request accelerated patent examination, if the applicant bears more of the examination burden and pays extra costs,” says​ Jeff Oelke.
In special cases, patent reviews can be expedited for a particular industry. For example,​ Bijal Vakil points to a recent US Patent and Trademark Office (PTO) “Green Technology” pilot program that preferentially advanced patent applications related to greenhouse gas reduction and sustainable energy. “An industry consortium could ask the PTO to consider similar accelerated procedures for reviewing patent applications for life-saving digital healthcare technologies,” he suggests.
Data privacy is a huge issue in digital healthcare, and most respondents (73%) fear the absence of standardized global privacy rules is a major barrier obstructing growth 81% of technology and 75% of life sciences companies say IP issues present barriers to growth in digital healthcare 90% of technology and 82% of life sciences companies said they would pursue a digital healthcare strategy even if they knew their products would not receive patent protection 92% of technology and 97% of life sciences companies would be likely to challenge a competitor’s granted patent at the US Patent and Trademark Office as opposed to litigating in federal court
Share via TwitterShare on FacebookShare on LinkedinShare on Google+